MétaCan
Menu
← Back to cohort
Record W4388979451 · doi:10.21037/tp-23-391

Maintaining excellent outcomes: the impact of age cutoff reclassification on reduced therapy for neuroblastoma patients

2023· letter· en· W4388979451 on OpenAlexaboutno aff
M. Jose Pérez‐García, Miguel F. Segura

Bibliographic record

VenueTranslational Pediatrics · 2023
Typeletter
Languageen
FieldMedicine
TopicNeuroblastoma Research and Treatments
Canadian institutionsnot available
FundersEuropean Regional Development FundInstituto de Salud Carlos III
KeywordsMedicineCutoffNeuroblastomaIntensive care medicinePediatrics

Abstract

fetched live from OpenAlex

Neuroblastoma, accounting for nearly 12-15% of childhood cancers, is the most prevalent and fatal extracranial solid malignancy affecting children.Nevertheless, despite its low incidence, with approximately 10 cases per million children under 15 years of age (8-10% of the total), neuroblastoma remains a significant clinical concern (1).Neuroblastoma primarily originates in the adrenal gland from neural crest precursor cells, that usually differentiate into adrenal chromaffin and sympathetic ganglion cells.However, it can emerge anywhere along the sympathetic nervous system chain.The exceptional feature of neuroblastoma lies in its diverse clinical behavior, as some tumors regress or mature, while others persist and progress despite intensive multimodal treatments.This variability in behavior closely correlates with a range of clinical and biological characteristics (2).Over the past few decades, extensive efforts have been made to increase the accuracy of the neuroblastoma risk classification system by integrating a variety of clinical and biological parameters.These advancements have facilitated the categorization of patients into low-, intermediate-risk, and high-risk groups.The Children's Oncology Group (COG) applies a set of criteria to categorize patient risk, which includes the patient's age at the time of diagnosis, the disease's extent as per the International Neuroblastoma Staging System (INSS), tumor characteristics determined by the International Neuroblastoma Pathology Classification (INPC) criteria, the MYCN gene status, and the DNA index or tumor cell ploidy (3).Older age has long been associated with poorer outcomes in neuroblastoma since the 1970's.Previous studies indicated that children over 12 months of age at diagnosis had inferior outcomes (4).This evidence was also supported by evidence generated from neuroblastoma mass screening programs conducted in Japan, Quebec and North America, and UK (5).Later on, a retrospective analysis by London et al. from Pediatric Oncology Group (POG) and Children's Cancer Group (CCG) studies revealed that 18 months was a better age cut-off for risk stratification (6).Regarding to the disease stage, Evans et al. described the first staging system for neuroblastoma in 1970, based on both, the site of origin, metastatic spread and the clinical behavior of the tumor (7).Later, an international panel of experts came together to establish a surgical staging system with the aim of facilitating the comparison of outcomes and treatment approaches across different countries.In 1988, the INSS was initially introduced and later revised

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.024
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Commentary · Consensus signal: none
Teacher disagreement score0.004
Threshold uncertainty score0.021

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.024
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0010.000
Scholarly communication0.0020.002
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.081
GPT teacher head0.362
Teacher spread0.282 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueTranslational Pediatrics→Same topicNeuroblastoma Research and Treatments→French-language works237,207→